Business
CYduct Diagnostics, Inc. Issues Annual Shareholder Update and Letter from the President
CYduct Diagnostics, Inc. Issues Annual Shareholder Update and Letter from the President.
About this update from Cyduct Diagnostics Inc.
[{"type":"text","content":"WESTPORT, CT / ACCESSWIRE / August 18, 2022 / CYduct Diagnostics, Inc. (OTC PINKK:CYDX), a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness, today provides a corporate update and letter from President, Dominick Gatto.Dear Shareholders,Upon changing our ticker symbol to "CYDX", we have taken further initiatives to develop, refine and execute our strategy to position our company to execute our strategic plans.The Company has retained the public accounting firm TPS Thayer, LLC to complete our audit with the aim of becoming a fully reporting company by early 2023.We have also appointed Anthony L.G., PLLC as our Corporate and Securities counsel. The firm's principal, Laura Anthony Esq., and her team have significant experience in assisting companies in creating and executing innovative and strategic legal plans.We have also engaged an investor relations firm, headed by Preya Narain, that is committed to providing our shareholders transparent access to company milestone achievements through continued communications, through formal press releases as well as through our corporate social media platforms.Acquisition & ResearchOver the past year, we are proud to have achieved several milestones for our company:HHC PREFERRED LLC.: CYduct successfully acquired the assets of HHC Preferred LLC (HHC) including the technology embodied in HHC"s patented, noninvasive device that is used to obtain nipple aspirate fluid (''NAF''). The assets included Intellectual property, finished goods inventory, manufacturing tooling, FDA regulatory 510K clearance and other materials pertinent to the device and its history.Proteomic Research Agreement with Yale University: CYduct entered into a Sponsored Research Agreement with Yale University that will facilitate the testing, development and performance of the University's patented nanowire biosensor technology to detect critical protein biomarkers that have been shown to be indicative of breast health and risk of breast cancer. This Agreement also grants CYduct an exclusive option to license this technology.BioCT: CYduct joined BioCT, Connecticut's Biosciences Community. For more information, please visit www.bioct.orgPartnerships & DevelopmentWe expect the remainder of 2022 to be a building period for our company, ...